Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
Lantern Pharma Inc. (LTRN)
Company Research
Source: Business Wire
Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half of 2024; with additional next-generation drug development programs approaching IND studies.Dosed initial patients in both Phase 1 clinical trials for synthetic lethal drug-candidates, LP-184 and LP-284, each of which are first-in-human molecules with the potential for use across multiple cancer indications.Expanded Phase 2 LP-300 Harmonic™ clinical trial into 12 sites in the US and advanced towards initial regulatory allowance for trial commencement in Japan, Taiwan and South Korea where approximately 30-35+% of all lung cancer cases occur in never-smokers with NSCLC.Advanced Starlight Therapeutics with hiring of Chief Medical Officer (CMO) and preparing for potential Phase 1B/2 clinical trial in adult CNS tumors beginning in second half of 2024.Demonstrated significant advancement of our cryptophycin focused antibody-drug-conjugate program (cp
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Lantern Pharma Inc. (NASDAQ: LTRN) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentBusiness Wire
- Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanBusiness Wire
LTRN
Earnings
- 3/18/24 - Beat
LTRN
Analyst Actions
- 4/25/24 - HC Wainwright
LTRN
Sec Filings
- 4/26/24 - Form 144
- 4/26/24 - Form 144
- 4/26/24 - Form 144
- LTRN's page on the SEC website